What happened
124I-evuzamitide PET/CT demonstrates 94% sensitivity and high specificity for diagnosing cardiac amyloidosis.
Cardiac Imaging · Cedars-Sinai Medical Center
@MasriAhmadMD Thank you @MasriAhmadMD for this excellent summary and for enrolling the largest number of participants in the REVEAL study!
REVEAL co-authorCardiac Imaging · Cedars-Sinai Medical Center
@JAMA_current Diagnosis of cardiac amyloidosis with a single test-I124 evuzamitide PET/CT: a (-) scan excludes and a (+) scan confirms it. Can image multiple amyloid types and in multiple organs. Grateful to the commitment of patients, investigators, & study committees of the REVEAL trial.
REVEAL co-authorCardiac Imaging · Cedars-Sinai Medical Center
These I 124 evuzamitide data demonstrate the potential of a single test to help health care providers identify or exclude cardiac amyloidosis. Clinically, a sensitive, specific and quantitative PET tracer could help distinguish cardiac amyloidosis from other causes of heart failure, differentiate amyloid subtypes when used alongside appropriate laboratory testing, and track changes in cardiac amyloid burden over time.
REVEAL co-authorMunich, 8yrs after our beloved, late Prof Rapezzi presented 1st effective ATTR-CM therapy, @DorbalaSharmila presented #REVEAL -poised to reshape #amyloidosis diagnosis: cardiac & systemic. Privileged to contribute & grateful to patients who made this possible. Full circle moment.
t.coREVEALHeart Failure · Brigham and Women's Hospital
@DorbalaSharmila presented the results of the #REVEAL study - Evuzamitide PET/CT in cardiac amyloidosis Amazing results of this first ever rigorously conducted multicenter trial of an imaging agent in cardiac amyloidosis We are so thankful for the commitment of patients and
t.coREVEALBayer (Germany)
We are very excited about the positive topline results of the REVEAL study and are looking forward to sharing the data with the scientific community.
REVEALStanding room only, doors closed at #ESC2026 for #REVEAL! An exciting moment as @DorbalaSharmila presents findings that’ll reshape the diagnosis of amyloidosis… cardiac and systemic.@Ron_Witteles @MasriAhmadMD @MathewMaurer @MargotDavisMD @spencerdguthrie @abouezzeddine
t.coREVEALOpen questions from this trial that would benefit from expert input.
Answers are grounded in this paper and cite their sources.
Why the trial, tables, limitations, PICO, abstract, media & sources
Cardiac amyloidosis is diagnosed late, and current imaging cannot reliably detect and quantify both AL and ATTR disease. REVEAL asked whether 124I-evuzamitide PET/CT, a pan-amyloid tracer, accurately diagnoses cardiac amyloidosis.
Does 124I-evuzamitide PET/CT accurately diagnose cardiac amyloidosis in adults with suspected disease?
| Outcome | PET/CT |
|---|---|
| Sensitivity for cardiac amyloidosis Coprimary endpoint · p<0.001 | PET/CT 94% (95% CI 85-98) |
| Specificity for cardiac amyloidosis Coprimary endpoint · p<0.001 | PET/CT 86% (95% CI 77-92) |
| Positive / negative predictive value Secondary accuracy measures · PPV 95% CI 75-92; NPV 95% CI 87-98 | PET/CT 85% / 94% |
Does 124I-evuzamitide PET/CT accurately diagnose cardiac amyloidosis in adults with suspected disease?
124I-evuzamitide PET/CT is a highly sensitive (94%) and specific (86%) noninvasive imaging modality for diagnosing cardiac amyloidosis.
The few experts who have posted, including the presenter, see this imaging scan as a promising single test to confirm or rule out cardiac amyloidosis, and no one has pushed back so far.
The trial's presenter describes the scan as one test that can both rule out and confirm cardiac amyloidosis, across more than one amyloid type and organ. Another voice praises the trial as an unusually rigorous multicenter study of an imaging agent in this disease. No independent critique has been posted yet, so it is still open how this test would fit alongside current diagnostic workups.
1 take classified by contention axis so far — the map appears as more land.
Supports noninvasive diagnosis of cardiac amyloidosis; extends direct PET imaging beyond TTR subtypes.
Importance: Diagnosing cardiac amyloidosis remains challenging because current imaging approaches are limited to transthyretin amyloidosis. A noninvasive test capable of directly imaging cardiac amyloidosis from various amyloid types and in multiple organs could address an important unmet diagnostic need. Objective: To evaluate the sensitivity and specificity of 124I-evuzamitide positron emission tomography (PET)/computed tomography (CT) for diagnosing cardiac amyloidosis. Design, Setting, and Participants: Prospective, multicenter (18 US centers), single-group study evaluating the efficacy of 124I-evuzamitide to diagnose cardiac amyloidosis. This study was conducted from January 14, 2025, to March 12, 2026, including a 60-day follow-up period. Three physicians with cardiac PET/CT experience independently reviewed PET/CT images for visual cardiac 124I-evuzamitide uptake while blinded to clinical data. Three expert clinical amyloidosis physicians, blinded to PET/CT data, independently adjudicated the diagnosis based on the standard-of-care diagnostic algorithm. A total of 195 adults suspected of having cardiac amyloidosis were enrolled when they presented for diagnostic evaluation at participating institutions, excluding patients with an established diagnosis of cardiac or systemic amyloidosis. Interventions: PET/CT scans were obtained 3 to 5 hours after intravenous administration of 1 mCi of 124I-evuzamitide. Potassium iodide (130 mg) was given orally for 3 days starting at least 30 minutes prior to 124I-evuzamitide injection. Main Outcomes and Measures: Coprimary end points of this study were to assess the sensitivity and specificity of 124I-evuzamitide for the diagnosis of cardiac amyloidosis. Results: Overall, 170 patients were included (median [IQR] age, 72 [64-79] years; 75.3% male, 19.2% Black, 79.0% White). Median N-terminal pro-brain natriuretic peptide was 471 pg/mL and 61.7% had New York Heart Association class II or III heart failure symptoms. The overall sensitivity was 94% (95% CI, 85%-98%; P < .001); specificity, 86% (95% CI, 77%-92%; P < .001); positive predictive value, 85% (95% CI, 75%-92%); and negative predictive value, 94% (95% CI, 87%-98%). Conclusions and Relevance: 124I-evuzamitide PET/CT is highly sensitive and specific for diagnosing cardiac amyloidosis with an acceptable safety profile. These results support 124I-evuzamitide PET/CT as a diagnostic test to evaluate patients with suspected cardiac amyloidosis. Trial Registration: ClinicalTrials.gov Identifier: NCT06788535.
Dorbala et al. (2026) studied suspected cardiac amyloidosis (n=170). 124I-evuzamitide PET/CT vs. standard-of-care diagnostic algorithm was evaluated on sensitivity and specificity of 124I-evuzamitide for the diagnosis of cardiac amyloidosis (Sensitivity 94%, 95% CI 85-98, p=<.001). 124I-evuzamitide PET/CT demonstrated high diagnostic accuracy for cardiac amyloidosis, with a sensitivity of 94% and specificity of 86%.
Synapse has enriched 10 related papers. Consider them for comparative context: